PAS-IL-1Ra
Pre-clinical- Indications
- Autoinflammatory diseases, Cancer
Company intelligence / Profile preview
DNX Biopharmaceuticals, Inc.
Irvine or San Diego*, California, United Statesdnxbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
DNX Biopharmaceuticals develops long-lasting therapeutic proteins targeting chronic and inflammatory diseases. Its programs are in preclinical stages and leverage proprietary technologies such as PASylation® to enhance drug properties. The company has partnerships with Johnson & Johnson Innovation – JLABS and XL-protein[3]. No clinical results have been published yet.
- Therapeutic areas
- EndocrinologyRheumatologyImmunologyInfectious Diseases
- Modalities
- Therapeutic proteins (long-acting)Small moleculesSingle-chain FV antibody fragments
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Johnson & Johnson Innovation – JLABS[3]XL-protein GmbH[3]
Beyond the preview
Go deeper on DNX Biopharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNX Biopharmaceuticals, Inc..